Align Technology

ALGN · NASDAQ

$150.50+$1.50 (+1.00%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $149.00

ALGN analyst rating

BuyConsensus of 12 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy8
Hold4
Underperform0
Sell0

12-month price target · 18 analysts

Average $211.78 (+40.7% upside)

Low: $171.70
Now: $150.50
High: $246.75

Upgrades and downgrades

The latest rating actions, newest first

ALGN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Baird	Oct 15, 2026	Downgrade	Outperform → Neutral	$218.00 → $162.00	55%
Leerink Partners	Oct 14, 2026	Maintains	Outperform	$235.00 → $215.00	61%
Stifel	Oct 9, 2026	Maintains	Buy	$210.00 → $175.00	55%
Evercore ISI Group	Oct 5, 2026	Downgrade	Outperform → In-Line	$220.00 → $155.00	60%
UBS	Jul 23, 2026	Maintains	Neutral	$186.00 → $189.00	70%
BMO Capital	Jul 9, 2026	Initiates	Outperform	$209.00	45%
Evercore ISI Group	Apr 30, 2026	Maintains	Outperform	$200.00 → $220.00	60%
Mizuho	Apr 30, 2026	Maintains	Outperform	$215.00 → $220.00	54%
Morgan Stanley	Apr 24, 2026	Maintains	Equal-Weight	$169.00 → $188.00	62%
Piper Sandler	Apr 21, 2026	Maintains	Overweight	$220.00 → $235.00	43%

The case for and against

Updated Jul 28, 2026

Bull case

Align Technology is positioned well in a large and under-penetrated market with its dominant market share and a strong network of trained providers. The company's recent results have shown impressive breadth across geographies and channels, with strong demand for both its Invisalign clear aligners and iTero intraoral scanners. The company's management has set reasonable guidance for 2026, with expectations for continued growth and improved margins, giving investors increasing confidence in the stock's performance.

Bear case

Align Technology is heavily reliant on its Invisalign product, which controls over 90% of the clear aligner market. However, with an estimated 10% of all orthodontic cases treated by Invisalign in 2022 and a total of 14 million patients treated since launch, it is facing a saturated market. Additionally, the company's other product, iTero intraoral scanners, only capture a little over half of digital scans and face increasing competition from other digital scanning options, making it harder for them to maintain market dominance and sustain long-term growth.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.